33 results on '"Beelen, Dietrich"'
Search Results
2. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
3. Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
4. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
5. Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation
6. Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
7. Microbiologic Diagnostic Workup of Acute Respiratory Failure with Pulmonary Infiltrates after Allogeneic Hematopoietic Stem Cell Transplantation: Findings in the Era of Molecular- and Biomarker-Based Assays
8. Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study
9. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation
10. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
11. Clinical Utility of Quantitative PCR for Chimerism and Engraftment Monitoring after Allogeneic Stem Cell Transplantation for Hematologic Malignancies
12. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
13. Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
14. Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine
15. Comparison of Cytogenetic Clonal Evolution Patterns following Allogeneic Hematopoietic Transplantation versus Conventional Treatment in Patients at Relapse of AML
16. Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
17. Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS) Using Treosulfan Based Compared to Standard Reduced-Intensity or Myeloablative Conditioning Regimens. a Report of the Chronic Malignancies Working Party of EBMT
18. Allogeneic Stem Cell Transplantation for AML Patients with RUNX1 Mutation in First Complete Remission: A Study on Behalf of the ALWP of the EBMT
19. The Role of Measurable Residual Disease (MRD) at Time of Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia Transplanted after Myeloablative Conditioning. A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
20. Secondary AML Is an Independent Risk Factor for Outcome after SCT in First Complete Remission - a Registry-Based Comparison to De Novo AML on Behalf of the EBMT Acute Leukemia Working Party
21. Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens
22. Comprehensive Clinical-Molecular Transplant Risk Model for Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation
23. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia over 70 Years of Age: On Behalf of the Acute Leukemia Working Party of the EBMT
24. Outcomes of Allogeneic Hematopoietic Cell Transplantation for AML with Complex Karyotypes: A Retrospective Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and MD Anderson Cancer Center
25. What Is the Outcome of Patients with Acute Leukemia Who Survive Severe Acute Graft-Versus-Host Disease?
26. Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation
27. The Functional Distance Between Mismatched HLA-DPB1 Increases Risks of Relapse and Mortality after Unrelated Donor Hematopoietic Cell Transplantation for AML, ALL and MDS: A Refinement of the T Cell Epitope Group Algorithm for Permissive Mismatches
28. Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT
29. 317 - Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia over 70 Years of Age: On Behalf of the Acute Leukemia Working Party of the EBMT
30. 452 - What Is the Outcome of Patients with Acute Leukemia Who Survive Severe Acute Graft-Versus-Host Disease?
31. 18 - Outcomes of Allogeneic Hematopoietic Cell Transplantation for AML with Complex Karyotypes: A Retrospective Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and MD Anderson Cancer Center
32. Who Is the Best Haematopoietic Stem Cell Donor for a Male Patient with Acute Leukaemia?
33. No Influence of V617F Mutation in JAK2 on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelofibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.